ENXTPA:SANPharmaceuticals
Sanofi Rare Disease Push Links AlphaDetect Sponsorship And Nexviazyme Partnership
Sanofi (ENXTPA:SAN) has been named the inaugural industry sponsor of the AlphaDetect initiative to advance early detection of Alpha-1 Antitrypsin Deficiency.
The company is also working with Maze Therapeutics to improve Pompe disease outcomes through the use of Nexviazyme.
These partnerships focus on rare respiratory and metabolic diseases, with an emphasis on earlier diagnosis and patient management.
For readers tracking ENXTPA:SAN, these moves sit within Sanofi’s rare disease and...